The International Neuromodulation Society

The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, mentorship, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.

Novel Coronavirus / COVID-19 Resources

The INS Peer-Reviewed Journal

The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online. The journal also has social media accounts on Twitter, Facebook, and Instagram.

journal cover

+Submit a Manuscript.+

What is Neuromodulation?

Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:

If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

Members may log in and visit the members-only section’s Global Discussion Forum

Breaking News Share

Company Seeks FDA Device Clearance for Treatment of Fibromyalgia

Oct. 7, 2021 - NeuroMetrix has submitted a request to the FDA for de novo clearance of the Quell external neurostimulation system as a prescription treatment for chronic pain symptoms of fibromyalgia. (Source: Seeking Alpha)

Authors Present Evidence for a Common Neurostimulation Treatment Pathway in Essential Tremor

Oct. 4, 2021 - A team of co-authors retrospectively analyzed a cohort of individuals with essential tremor who had been treated with unilateral deep brain stimulation. To predict outcome of stimulation targets that share a common tract, the authors correlated percentage of contralateral improvement with structural connectivity measures using normative connectomes. (Source: NeuroImage: Clinical)

Observational Study Investigates Pulse-Dosing of Spinal Cord Stimulation and Recharge Patterns

Oct. 2, 2021 - A prospective, multicenter, observational study investigated intermittent stimulation with 10 kHz spinal cord stimulation and device recharge time. (Source: Pain Medicine)

To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.

Continue Reading News Briefs

SAVE THE DATE: International Neuromodulation Society 3rd Interim Meeting, Nov. 11-13, 2022, Mumbai, India